JNJ

230.34

+1.88%↑

ABT

93.92

+1.12%↑

MDT

82.71

-0.91%↓

A

114.89

-1.04%↓

VEEV

160.81

-0.67%↓

JNJ

230.34

+1.88%↑

ABT

93.92

+1.12%↑

MDT

82.71

-0.91%↓

A

114.89

-1.04%↓

VEEV

160.81

-0.67%↓

JNJ

230.34

+1.88%↑

ABT

93.92

+1.12%↑

MDT

82.71

-0.91%↓

A

114.89

-1.04%↓

VEEV

160.81

-0.67%↓

JNJ

230.34

+1.88%↑

ABT

93.92

+1.12%↑

MDT

82.71

-0.91%↓

A

114.89

-1.04%↓

VEEV

160.81

-0.67%↓

JNJ

230.34

+1.88%↑

ABT

93.92

+1.12%↑

MDT

82.71

-0.91%↓

A

114.89

-1.04%↓

VEEV

160.81

-0.67%↓

Search

Simulations Plus Inc

Abierto

SectorSanidad

14.8 -0.07

Resumen

Variación precio

24h

Actual

Mínimo

14.27

Máximo

14.94

Métricas clave

By Trading Economics

Ingresos

3.9M

4.5M

Ventas

5.9M

24M

BPA

0.35

Rentabilidad por dividendo

0.48

Margen de beneficios

18.669

Empleados

212

EBITDA

4.9M

7.2M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+9.89% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.48%

2.24%

Próximas Ganancias

13 jul 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

51M

302M

Apertura anterior

14.87

Cierre anterior

14.8

Noticias sobre sentimiento de mercado

By Acuity

21%

79%

52 / 348 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

27 abr 2026, 23:15 UTC

Noticias de Eventos Importantes

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27 abr 2026, 23:08 UTC

Ganancias
Principales Movimientos del Mercado

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27 abr 2026, 23:58 UTC

Ganancias

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27 abr 2026, 23:58 UTC

Ganancias

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27 abr 2026, 23:56 UTC

Ganancias

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27 abr 2026, 23:56 UTC

Ganancias

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27 abr 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27 abr 2026, 23:42 UTC

Charlas de Mercado

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27 abr 2026, 23:34 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27 abr 2026, 23:30 UTC

Charlas de Mercado

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27 abr 2026, 23:08 UTC

Charlas de Mercado

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27 abr 2026, 23:02 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 abr 2026, 23:02 UTC

Charlas de Mercado

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27 abr 2026, 22:42 UTC

Charlas de Mercado

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27 abr 2026, 22:10 UTC

Ganancias

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27 abr 2026, 22:09 UTC

Ganancias

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27 abr 2026, 22:09 UTC

Ganancias

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27 abr 2026, 22:09 UTC

Ganancias

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27 abr 2026, 21:56 UTC

Ganancias

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27 abr 2026, 21:55 UTC

Ganancias

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27 abr 2026, 21:55 UTC

Ganancias

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27 abr 2026, 21:44 UTC

Ganancias

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27 abr 2026, 21:43 UTC

Ganancias

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27 abr 2026, 21:41 UTC

Ganancias

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27 abr 2026, 21:41 UTC

Ganancias

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27 abr 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 abr 2026, 20:50 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

27 abr 2026, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

27 abr 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

27 abr 2026, 20:39 UTC

Ganancias

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

9.89% repunte

Estimación a 12 Meses

Media 16 USD  9.89%

Máximo 16 USD

Mínimo 16 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

2

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

52 / 348 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat